929046-33-3
Chemical Structure
Elinzanetant
Synonym(s): NT-814; BAY3427080
- CAS No.: 929046-33-3
- Formula:C33H35F7N4O3
- Molecular Weight:668.64
IUPAC Name: 2-(3,5-bis(trifluoromethyl)phenyl)-N-(4-(4-fluoro-2-methylphenyl)-6-((7S,9aS)-7-(hydroxymethyl)hexahydropyrazino[2,1-c][1,4]oxazin-8(1H)-yl)pyridin-3-yl)-N,2-dimethylpropanamide
InChIKey: DWRIJNIPBUFCQS-DQEYMECFSA-N
SMILES: CC(C)(C1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1)C(N(C2=CN=C(N3[C@@H](CN4[C@@](COCC4)([H])C3)CO)C=C2C5=C(C=C(C=C5)F)C)C)=O
Biological Activity: Elinzanetant is an orally active and selective NK-1 and NK-3 receptor antagonist. Elinzanetant alleviates menopause-associated vasomotor symptoms, including hot flashes and night sweats. Elinzanetant reduces estradiol and progesterone levels. Elinzanetant can be used for the research of moderate to severe vasomotor and sleep disorders associated with menopause[1][2].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Elinzanetant | 99.82% | Elinzanetant is an orally active and selective NK-1 and NK-3 receptor antagonist. Elinzanetant alleviates menopause-associated vasomotor symptoms, including hot flashes and night sweats. Elinzanetant reduces estradiol and progesterone levels. Elinzanetant can be used for the research of moderate to severe vasomotor and sleep disorders associated with menopause. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Elinzanetant (Standard) | ≥98% | Elinzanetant (NT-814) Standard is the analytical standard of Elinzanetant (NT-814) (HY-109171). This product is intended for research and analytical applications. Elinzanetant is an orally active and selective NK-1 and NK-3 receptor antagonist. Elinzanetant alleviates menopause-associated vasomotor symptoms, including hot flashes and night sweats. Elinzanetant reduces estradiol and progesterone levels. Elinzanetant can be used for the research of moderate to severe vasomotor and sleep disorders associated with menopause. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Elinzanetant-d3 | Elinzanetant-d3 (NT-814-d3) is deuterium labeled Elinzanetant. Elizanetant (NT-814) is an orally active, selective NK-1,3 receptor antagonist. Elizanetant can reduce the levels of estradiol and progesterone, and is used in the study of vascular motor symptoms and sleep disorders related to menopause in women. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
-
Similarity Score 0.78
HY-129448RO4583298 -
Similarity Score 0.70
HY-19670Befetupitant -
Similarity Score 0.68
HY-16346Netupitant -
Similarity Score 0.68
HY-G0012Netupitant metabolite Monohydroxy Netupitant -
Similarity Score 0.68
HY-G0010Netupitant metabolite N-desmethyl Netupitant -
Similarity Score 0.67
HY-G0011Netupitant metabolite Netupitant N-oxide -
Similarity Score 0.66
HY-17615Fosnetupitant -
Similarity Score 0.66
HY-133206AFosnetupitant chloride monohydrochloride -
Similarity Score 0.61
HY-16346SNetupitant-d6 -
Explore the MedChemAI to find more analogs
References
- [1]. Schulz SI, et al. Mass Balance Recovery, Absorption, Metabolism, and Excretion of Elinzanetant in Healthy Human Volunteers and in vitro Biotransformation. Eur J Drug Metab Pharmacokinet. 2025;50(1):91-103. [Content Brief]
- [2]. Pawsey S, et al. Elinzanetant (NT-814), a Neurokinin 1,3 Receptor Antagonist, Reduces Estradiol and Progesterone in Healthy Women. J Clin Endocrinol Metab. 2021 Jul 13;106(8):e3221-e3234. [Content Brief]
